News

Lovinsky-Desir joins Lungcast on World Asthma Day to discuss community-specific burdens of disease, and emerging strategies to manage it.

Geneoscopy's ColoSense received FDA approval on May 06, 2024 based on data from the phase 3 CRC-PREVENT trial.

During this interview segment, Browning highlighted the impact of a future FDA acceptance of tapinarof for atopic dermatitis as well as the next milestones in regulatory approval.

Retina specialists and an AI screening tool trained to measure geographic atrophy agreed in a majority of cases, potentially expediting clinical trial enrollment and increasing consistency in measuring the disease.

At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.

Nelson discusses how personality disorder care has been slow to apply evidence into practice—and how it's affecting patients.

In an interview, Paul Appelbaum, MD, discussed issues clinicians will need to bring up to their patients if the FDA approves a psychedelic-assisted therapy.

In this Lungcast episode segment, Balmes spoke about advocating for air pollution improvements, inequities in air quality, and more.

Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.

The anti-VEGF agent tarcocimab significantly improved diabetic retinopathy severity score compared with SHAM in a phase 3 study.

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

Vitamin D concentration was significant in chronic hepatitis B virus but not hepatitis C virus infection, suggesting its potential impact on immune response.

In an interview, Ryan McLaughlin discussed the ethical concerns regarding treating psychiatric illness with cannabis.

The phase 2 trial failed to show improvement of ≥2-DRSS levels with the vorolanib intravitreal insert in patients with non-proliferative diabetic retinopathy.

The final in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on treatment considerations and therapeutic options for elevated Lp(a).

BI 764524 was well tolerated following intravitreal administration of single and multiple doses in the phase 1/2a trial, with signs pointing to early efficacy.

In this interview, Browning discusses his team’s trial data and the implications of the FDA’s decision to accept the supplemental new drug application for tapinarof as an eczema treatment.

Results showed the prevalence and treatment patterns for IgAN in select Asian Pacific countries and regions were not commonly available.

Devanand reviews lecanemab and the advent of blood biomarkers for dementia and Alzheimer's management at APA 2024.

Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.

Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.

In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.

Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.

In an interview with Andrew Chen, MD, he discussed the first-line treatment for generalized anxiety disorder and when to take other alterative medication.

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder.

Extended follow-up of a phase 1/2 trial finds hydroxyurea dose optimization significantly improves clinical responses in children in sub-Saharan Africa with sickle cell.

These data shed light on several important findings related to perceptions of hair loss severity among specific groups with central centrifugal cicatricial alopecia and their QoL measures.